[1] 肖科, 赵东霞, 斯莹, 等. 艾滋病合并肺孢子菌肺炎患者短期预后的危险因素分析[J].国外医药(抗生素分册), 2022, 43(2):96-100. [2] Wu L,Zhang Z,Wang Y,et al. A model to predict in-hospital mortality in HIV/AIDS patients with Pneumocystis pneumonia in China: the clinical practice in real world[J]. Biomed Res Int, 2019, 2019:605-608. [3] 史东阳, 郑以山.艾滋病合并肺孢子菌肺炎58例临床分析[J].内科急危重症杂志, 2020, 26(5):412-414. [4] Kann G, Wetzstein N, Bielke H, et al. Risk factors for IRIS in HIV-associated Pneumocystis pneumonia following ART initiation[J]. J Infect, 2021, 83(3):347-353. [5] Bozorgomid A,Hamzavi Y,Heidari KS,et al. Pneumocystis jirovecii pneumonia and human immunodeficiency virus co-infection in Western Iran[J]. Iran J Public Health, 2019, 48(11):2065-2069. [6] 中华医学会感染病学分会艾滋病学组. 艾滋病诊疗指南(第三版)[J]. 中华传染病杂志, 2015, 33(10):577-593. [7] 阴赪宏. 肺孢子菌肺炎诊断与治疗[M]. 北京: 中国科学技术出版社, 2013: 26-27. [8] Rafat Z,Ashrafi K,Hashemi SJ,et al. The mycological and molecular study of Pneumocystis jiroveci pneumonia among HIV and non-HIV immunocompromised patients hospitalized in pulmonary units in Guilan, Northern Iran[J]. Iran J Microbiol, 2021, 13(4):518-524. [9] 陈涛, 蒋忠胜, 李敏基, 等. 艾滋病合并肺孢子菌肺炎患者近期预后的COX回归分析[J].中国艾滋病性病, 2021, 27(5):467-471. [10] Hammarstrom H,Grankvist A,Broman I,et al. Serum-based diagnosis of Pneumocystis pneumonia by detection of Pneumocystis jirovecii DNA and 1,3-beta-D-glucan in HIV-infected patients: a retrospective case control study[J]. BMC Infect Dis, 2019, 19(1):658-661. [11] 袁婧, 邓长刚, 李奇穗, 等. 艾滋病合并重症肺孢子菌肺炎289例预后危险因素的回顾性分析[J].中国感染与化疗杂志, 2020, 20(6):594-600. [12] Almaghrabi RS,Alfuraih S,Alohaly R,et al. Pneumocystis jiroveci pneumonia in HIV-positive and HIV-negative patients: a single-center retrospective study[J]. Tanaffos, 2019, 18(3):238-243. [13] 石永兴, 杨海峰, 潘涛, 等.艾滋病合并肺孢子菌肺炎患者的临床表现及影像分析[J].中国煤炭工业医学杂志, 2016, 19(12):1724-1728. [14] 谢正平, 朱斌. 艾滋病合并肺孢子菌肺炎的CT表现分型与预后相关性[J].临床放射学杂志, 2018, 37(2):228-232. [15] 邵明梅, 高栋, 张德忠.研究分析CT诊断艾滋病合并肺孢子菌肺炎的影像特征[J].影像研究与医学应用, 2017, 1(8):164-166. [16] 黄大勇, 兰慧慧.艾滋病合并肺孢子菌肺炎144例临床分析[J].华夏医学, 2020, 33(3):155-157. [17] Wang H,Chang Y,Cui ZZ,et al. Admission C-reactive protein-to-albumin ratio predicts the 180-day mortality of AIDS-related Pneumocystis pneumonia[J]. AIDS Res Hum Retroviruses, 2020, 36(9):753-761. [18] 李爱新, 黄春洋, 张宏伟, 等.血清白蛋白对艾滋病合并重度肺孢子菌肺炎患者预后的评估价值[J].医学研究杂志, 2017, 46(6):129-132,139. [19] Sun J, Su J, Xie Y, et al. Plasma IL-6/IL-10 ratio and IL-8, LDH, and HBDH level predict the severity and the risk ofdeath in AIDS patients with Pneumocystis pneumonia[J]. J Immunol Res, 2016, 24(18):51-54. [20] Dunbar A,Schauwvlieghe A,Algoe S,et al. Epidemiology of Pneumocystis jirovecii pneumonia and (non-)use of prophylaxis[J]. Front Cell Infect Microbiol, 2020, 10(15):224-227.
2023, Vol. 30 
